Halozyme Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Halozyme Therapeutics (HALO) Misses Q1 EPS by 1c; Reiterates Outlook
May 9, 2017 4:28 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $30.85 million.
Financial Outlook for 2017
For 2017, the company reiterated its financial guidance of:
Net revenue of $115... More